The pharmaceutical consulting industry in Benelux is rapidly evolving, characterized by innovation and a strong presence of biotech companies. Operating primarily in Luxembourg, Belgium, and the Netherlands, firms vary in focus, from drug development to regulatory affairs. These companies often collaborate with researchers and healthcare organizations to address critical medical needs and drive advancements in treatments. The industry is currently steering towards increased emphasis on personalized medicine and digital health solutions, as well as greater integration of technology in consultancy services. Interest in biotech startups is surging, highlighting an optimistic outlook for the sector.


This sector is represented by a mix of venture capital firms, corporate investors, and private equity groups, with notable representation from locations like Amsterdam and Brussels. In 2024, these investors collectively executed 99 deals, showcasing their active roles in supporting the pharmaceutical landscape. Institutions range from smaller capital funds like V-Bio Ventures, founded in 2015, to established entities such as the European Investment Bank, established in 1958. These investors prioritize healthcare, particularly in innovative startups targeting unmet medical needs.


Top 14 Pharmaceutical Consulting Investors in Benelux


1. European Innovation Council (EIC)


The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, the EIC offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. In 2022, the EIC provided a grant of $2,425,610 to Abzu, a company that may be involved in pharmaceutical innovations. Additionally, in 2025, Precisionlife raised $2,607,967 through a grant from the EIC, indicating its support for advancements in precision medicine. Qubit Pharmaceuticals, which has received multiple grants from the EIC, including $2,998,774 in 2021 and €16.1 million in a seed round, is another example of the EIC's involvement in the pharmaceutical sector. These transactions highlight the EIC's role in fostering innovation in pharmaceuticals, making it a relevant player in the pharmaceutical consulting landscape.


2. Forbion

  • Website: forbion.com
  • Type: Venture Capital
  • Headquarters: Naarden, North Holland, Netherlands
  • Founded year: 2006
  • Headcount: 11-50
  • Number of deals in 2024: 23
  • LinkedIn: forbion-capital-partners

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, Netherlands. The firm specializes in the life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative therapies and technologies aimed at improving patient outcomes. Notable transactions include leading a $28M seed financing round for Orbis Medicines, which focuses on developing macrocycle drugs, and co-leading a $53M Series B funding for Amphista Therapeutics, which is involved in innovative therapeutic solutions. These investments highlight Forbion's commitment to advancing pharmaceutical innovations and addressing unmet medical needs, reinforcing its relevance in the pharmaceutical consulting industry.


3. European Investment Bank (EIB)


The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In the pharmaceutical consulting context, the EIB has been involved in several notable transactions. For instance, it provided €15 million in funding to IRBM SpA to expand research into coronavirus and other infectious diseases, demonstrating its commitment to supporting health-related initiatives. Additionally, the EIB has participated in debt financing for Evotec, a prominent player in the pharmaceutical industry, raising substantial amounts in post-IPO debt. These transactions highlight the EIB's active role in financing pharmaceutical research and development, making it a significant investor in this field.


4. Life Sciences Partners (LSP)

  • Website: lspvc.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 1987
  • Headcount: 11-50
  • Number of deals in 2024: 15
  • LinkedIn: lsp-bioventures

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, Netherlands, founded in 1987. The firm specializes in private equity investments within the healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include their involvement with Amolyt Pharma, where they participated in multiple funding rounds (Series A, B, and C) totaling over $138 million, aimed at advancing therapeutics for rare endocrine disorders. Additionally, LSP's early investment in KuDOS Pharmaceuticals Ltd highlights their long-standing commitment to supporting pharmaceutical innovation. Their portfolio reflects a strategic focus on companies that are likely to benefit from consulting services in the pharmaceutical space, making them a relevant player in this industry.


5. M Ventures

  • Website: m-ventures.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 2009
  • Headcount: 11-50
  • Number of deals in 2024: 18
  • LinkedIn: merck-ventures

M Ventures is a venture capital fund based in Amsterdam, Netherlands, founded in 2009. The firm specializes in investing in transformative ideas within the biotechnology and technology sectors, with a strong focus on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping them achieve commercial success. Notable transactions include a €20M Series A financing for Calypso Biotech, aimed at developing an anti-Interleukin-15 antibody for autoimmune diseases, and a £37.5 million Series A round for Nucleome Therapeutics, which focuses on exploring the human genome for drug discovery. These investments highlight M Ventures' commitment to supporting innovative companies in the pharmaceutical space, making them a significant player in the industry.


6. Eurofins

  • Website: eurofins.com
  • Type: Corporate
  • Headquarters: Luxembourg
  • Founded year: 1987
  • Headcount: 10001+
  • Number of deals in 2024: 8
  • LinkedIn: eurofins

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. With a workforce exceeding 10,000 employees, Eurofins provides a comprehensive range of analytical and testing services across various industries, including pharmaceuticals, food, and environmental sectors. The company has a global presence, operating over 900 laboratories in 62 countries, which allows them to offer extensive expertise in testing and diagnostics. Notably, Eurofins has made several strategic acquisitions in the pharmaceutical sector, such as the acquisition of Advinus Therapeutics in 2017, which marked Tata's exit from the pharmaceutical sector. This acquisition highlights Eurofins' commitment to enhancing its pharmaceutical capabilities. Additionally, they acquired Eurofins CDMO Alphora in 2017, further solidifying their position in drug development and manufacturing. Other relevant acquisitions include Optimed SA, Eurofins Biolab Srl, and Laboratorios Ecosur, all of which contribute to their extensive service offerings in the pharmaceutical consulting space.


7. Gilde Healthcare


Gilde Healthcare is a venture capital firm based in Utrecht, Netherlands, specializing in healthcare investments. Founded in 1982, the firm manages over €2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and therapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Gilde Healthcare acquired a majority stake in KLIFO A/S, a Danish drug development consultancy, in May 2021, aiming to enhance KLIFO's service offerings and geographical reach. This acquisition highlights Gilde's commitment to supporting companies that provide consulting services within the pharmaceutical sector. Additionally, Gilde has been involved in various funding rounds for companies like Amphista Therapeutics and Viroclinics Biosciences, further demonstrating their active role in the healthcare and pharmaceutical consulting landscape.


8. Gimv

  • Website: gimv.com
  • Type: Venture Capital
  • Headquarters: Antwerp, Flanders, Belgium
  • Founded year: 1980
  • Headcount: 51-200
  • Number of deals in 2024: 8
  • LinkedIn: gimv

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges. Notably, Gimv has been involved in several significant transactions in the pharmaceutical sector, such as the Series C funding of TorreyPines Therapeutics, which raised $34.8 million in 2005, and the Series B funding of PamGene, which raised over $11 million in 2003. Additionally, Gimv acquired a 20.87% stake in BioConnection, a company that plays a role in the pharmaceutical supply chain, further demonstrating their engagement in the healthcare and life sciences industries.


9. BGV (BioGeneration Ventures)


BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, North Holland, Netherlands, founded in 2006. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help these companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include a $60 million Series A investment in AcertaPharma in 2013, which is involved in developing therapies for cancer, and a recent $65 million Series B investment in Confo Therapeutics in 2024, which focuses on drug discovery and development. These investments demonstrate BGV's commitment to supporting companies that are at the forefront of pharmaceutical innovation, making them a relevant player in the pharmaceutical consulting landscape.


10. Noshaq

  • Website: noshaq.be
  • Type: Venture Capital
  • Headquarters: Belgium
  • Founded year: 1985
  • Headcount: 11-50
  • Number of deals in 2024: 11
  • LinkedIn: noshaq-be

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that focuses on providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in the province of Liege. The firm specializes in funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in several significant transactions in the pharmaceutical and biotech sectors, including a €15 million funding round for Hyloris Pharmaceuticals, which focuses on innovative drug delivery systems. They also invested in THERAtRAME SA, which is developing new therapeutics for cancer, and Radiomics, which is working on imaging AI solutions for lung cancer. These investments highlight Noshaq's commitment to supporting advancements in the pharmaceutical industry.


11. Cvc

  • Website: cvc.com
  • Type: Private Equity
  • Headquarters: Luxembourg
  • Founded year: 2005
  • Headcount: 1001-5000
  • Number of deals in 2024: 16
  • LinkedIn: cvc-capital-partners

CVC Capital Partners is a prominent private equity firm based in Luxembourg, founded in 2005. The firm specializes in private equity, credit, secondaries, and infrastructure, managing approximately €193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC focuses on delivering sustainable value and growth through strategic investments. Among their notable transactions in the pharmaceutical sector, CVC acquired Genetic SpA in July 2020 and a controlling stake in Recordati S.p.A. in June 2018. Additionally, they acquired a 50% stake in DFE Pharma, a key player in the pharmaceutical excipients market, in September 2019. These transactions illustrate CVC's active engagement in the pharmaceutical industry, making them a relevant investor in the pharmaceutical consulting space.


12. Thuja Capital

  • Website: thujacapital.com
  • Type: Venture Capital
  • Headquarters: Utrecht, Utrecht, Netherlands
  • Founded year: 2006
  • Headcount: 1-10
  • Number of deals in 2024: 3
  • LinkedIn: thuja-capital

Thuja Capital Management BV is a venture capital firm based in Utrecht, Netherlands, founded in 2006. The firm specializes in healthcare investments, providing funding and strategic guidance to innovative healthcare ventures from start-up to scale-up. Their primary focus is on biotech and medtech sectors, making them a key player in supporting companies that develop novel therapies and medical technologies. Notable transactions include their participation in the Series A financing round for InnoSIGN, which raised $8M to support its growth and clinical validation studies, and their investment in argenx, which raised $4.5M in a Series A round. These investments highlight Thuja Capital's commitment to advancing healthcare innovations, positioning them as a relevant investor in the pharmaceutical consulting space.


13. Droia Ventures

  • Website: droiaventures.com
  • Type: Venture Capital
  • Headquarters: Zaventem, Flanders, Belgium
  • Founded year: 2011
  • Headcount: 11-50
  • Number of deals in 2024: 5
  • LinkedIn: droiaventures

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in the life sciences sector, focusing on investments in drug development companies. They provide essential support for clinical proof of concept and scientific validation of innovative therapies, primarily targeting oncology and genetic diseases. Their clientele consists of biotechnology firms seeking funding and expertise to advance their therapeutic innovations. Notable transactions include a $55 million Series A financing round for Actio Biosciences, which is leveraging its genetics platform to develop therapeutics for various diseases. Additionally, Droia Ventures has participated in multiple funding rounds for Frontier Medicines, which focuses on precision oncology and targeted protein degradation, raising significant amounts in Series A, B, and C rounds. These investments highlight Droia Ventures' commitment to advancing pharmaceutical innovations and their active role in the consulting landscape of the industry.


14. Wolters Kluwer

  • Website: wolterskluwer.com
  • Type: Corporate
  • Headquarters: Alphen Aan Den Rijn, South Holland, Netherlands
  • Founded year: 1836
  • Headcount: 10001+
  • Number of deals in 2024: 4
  • LinkedIn: wolters-kluwer

Wolters Kluwer N.V. is a prominent information services company based in Alphen Aan Den Rijn, South Holland, Netherlands, founded in 1836. The company specializes in providing software solutions and services across various professional sectors, including healthcare, legal, tax, accounting, finance, and compliance. Wolters Kluwer supports professionals by offering tools that enhance productivity and ensure compliance with regulatory requirements. In the healthcare domain, they have made strategic acquisitions to bolster their offerings. For instance, they acquired Health Language, Inc., a medical terminology content and mapping vendor, which enhances their capabilities in healthcare data management. Additionally, their acquisition of Pharmacy OneSource, a leading SaaS provider in the hospital pharmacy market, further solidifies their position in the healthcare sector. These transactions demonstrate Wolters Kluwer's commitment to improving healthcare services and information, making them a relevant player in the pharmaceutical consulting landscape.



Pharmaceutical Consulting Insights: Key Investors in Benelux


InvestorHeadquarterSizeFoundedDeals 2024
European Innovation Council (EIC)Brussels, Brussels, Belgium201-500195857
ForbionNaarden, North Holland, Netherlands11-50200623
European Investment Bank (EIB)Luxembourg1001-5000195899
Life Sciences Partners (LSP)Amsterdam, North Holland, Netherlands11-50198715
M VenturesAmsterdam, North Holland, Netherlands11-50200918
EurofinsLuxembourg10001+19878
Gilde HealthcareUtrecht, Utrecht, Netherlands51-200198212
GimvAntwerp, Flanders, Belgium51-20019808
BGV (BioGeneration Ventures)Naarden, North Holland, Netherlands1-1020066
NoshaqBelgium11-50198511
CvcLuxembourg1001-5000200516
Thuja CapitalUtrecht, Utrecht, Netherlands1-1020063
Droia VenturesZaventem, Flanders, Belgium11-5020115
Wolters KluwerAlphen Aan Den Rijn, South Holland, Netherlands10001+18364


Want to find more investors focusing on the pharmaceutical consulting industry?

If you want to find more investors that are active in the pharmaceutical consultingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!